“Recognition and Management of Prescription Opioid Failure and Abuse in the Primary Care Setting” William Morris, MD Medical Director Janus of Santa Cruz.

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

Introduction Medication non adherence ( noncompliance) remains a major problem. You have to assess and treat adherence related problems that can adversely.
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice Erin Inglis, MD a, Jessie Burch, PharmD b, Nida Awadallah, MD c,,
The purpose is not to imply everyone on controlled substances will become addicted!!! Everyone on controlled substances is, however, at increased risk.
Chronic Pain Management Elaine Wendt, MD. Pain is now “Fifth Vital Sign”
Identifying and Addressing Aberrant Medication Use Behaviors.
Pain and Chemical Dependency Not an “Either – Or” proposition Douglas Gourlay, MD, FRCPC, FASAM Wasser Pain Centre, Toronto ON.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Sublingual Buprenorphine and Pain
Best Practices Prescribing & Preventing Drug Diversion What All Nurses Must Know.
Medical Director Jackson County Health and Human Services
Substance Abuse Issues in Health Professionals Shannon V Chavez, MD Chair, UCSD Physician Well-Being Committee Director, UCSD Health Professional Program.
Substance Abuse Issues in Chronic Pain Management Steven D. Passik, PhD Director, Oncology Symptom Control and Research Community Cancer Care, Inc. Indianapolis,
Opioid Therapy of Chronic Pain: Evolving Trends Nociception Other physical symptoms Physical impairments NeuropathicPsychological Social isolation mechanismsprocessesFamily.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Chronic Opiate Therapy Benjamin Meeks, FNP. Agenda History of Opiate Therapy Risks of Opiate Therapy Benefits of Opiate Therapy Guidelines for Opiate.
How to Discuss Drug Issues with a Patient Greg L. Jones, MD Medical Director Kentucky Physicians Health Foundation.
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Senior Medical Director, Health Policy
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Steven D. Passik, PhD Director,
The Role of Clinical Pharmacists in Outpatient Psychiatric Clinics Mary A. Gutierrez, Pharm.D., BCPP Associate Professor of Clinical Pharmacy University.
Pain and Addiction: Assessment Issues Russell K. Portenoy, MD Chairman, Dept of Pain Medicine and Palliative Care Beth Israel Medical Center New York,
Slide 1 of xx Emerging Pharmacy Issues in the Texas Workers’ Compensation System Presented by Suzanne Novak, MD, PhD CEO, Austin Outcomes Research, Inc.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Concerns About Addiction: Bringing Clarity to Confusion about Addiction Terminology Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist.
Introduction to Pain/Opioid Management
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
Opioid Use in Work-related Injuries Pacific Northwest Chapter - Association of Occupational Health Professionals (AOHP) January 4, 2011 Jaymie Mai, PharmD.
For Pain or Not for Pain: Methadone Madness
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Medications for Pain: What You Need to Know for Treatment in Workers’ Compensation Suzanne Novak, MD, PhD 5/17/07.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Opioid Use in Workers’ Compensation Suzanne Novak, MD, PhD November 2008.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Opioid Compliance, Documentation, and Monitoring October 9, 2015.
Use of Opioids fro Chronic Pain in Primary Care Norman Wetterau MD
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Addiction and dependence Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Working with the Impaired Nurse Sharon S. Parker ONA convention, 2015.
Prevention, Identification and Treatment of Opioid Use Disorders: A Personal Perspective Leah Bauer, MD Medical Director, Addiction Resource Center, Mid.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
Chronic Pain Management Harald Lausen, DO, MA FCM Clerkship SIU School of Medicine.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Opioids Tapering Melissa B. Weimer, DO, MCR. Disclosures Dr. Weimer is a consultant for INFORMed, IMPACT education, and the American Association of Addiction.
Sarah Thompson, PharmD, CDOE Director of Clinical Services, Coastal Medical.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
A System to Manage Long Term Opioid Prescribing in the Primary Care Setting Joy Nassar, MD University Medicine Foundation November 16, 2015.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
What Our Patients Look Like
Current Concepts in Pain Management
Medication-Assisted Therapy at Coleman Profession Services
Pharmaceutical Care Plan
STOP! Safe Treatment of Pain
Opioid Prescribing & Monitoring
Recognize and respond to physician distress and suicidal behavior
Recognize and respond to physician distress and suicidal behavior
Assessing Opioid Use Disorder, part 1
Essentials of Good Pain Care: A Team-Based Approach
Tapering and Discontinuing Chronic Opioid Therapy
Bassett-UMass MAT ECHO.
Acute Pain Management & Addiction
Presentation transcript:

“Recognition and Management of Prescription Opioid Failure and Abuse in the Primary Care Setting” William Morris, MD Medical Director Janus of Santa Cruz

Chronic Pain: Burden of Disease 9 in 10 Americans regularly suffer from pain Each year approx 50 million Americans suffer from chronic pain Chronic pain is the most common cause of chronic disability Almost 1/3 of Americans will suffer from chronic pain at some point in their lives Pain: Current Understanding of Assessment, Management, and Treatments. National Pharmaceutical Council.

Overview Process for prescription of opioids for chronic non-cancer pain Opioid “failures” – excessive side effects – inadequate analgesia – Opioid “misuse” = opioid-related aberrant behaviors Clarification of terminology Recognizing and responding to aberrant opioid- related behaviors

Clinical Guidelines for Opioid Use in Chronic Pain 2010: American Society of Anesthesiologists – ice_G ice_G 2010: Drug Enforcement Agency – uideline_for_Chronic_Pain_Management_13.aspx 2009: Institute for Clinical Systems Improvement – 99/pain_chronic_assessment_and_management_of_guideline.html 99/pain_chronic_assessment_and_management_of_guideline.html 2009: Journal of Pain – (08) /fulltextwww.jpain.org/article/S (08) /fulltext 2004: Federation of State Medical Boards of the United States – : Veterans Administration Guideline –

Summary Process for Prescription Opioids Decision Phase Implementation Phase Goals metGoals not met Outcome Phase

Decision Phase – Are Opioids Needed? Pain is moderate to severe Pain has significant impact on function and quality of life Non-opioid therapies have failed

Decision Phase- Are Opioid Benefits > Risks? Strongest risk factors for abuse – History of substance abuse personally/family – Psychiatric comorbidity: severe depression/anxiety – History of drug-related crime – Regular contact with high risk group (substance abusers) – History of Sexual abuse – preadolescent – Smokers - Ives T el al. BMC Health Services Research Redi MC et al. JGIM Michna E et al. JPSM Akbik H et al. JPSM 2006

Decision for Opioids - Benefit > Risk? (cont.) Risk assessment tools: – Opioid Risk Tool: Webster LR and Webster RM. Pain Medicine.2005;6; – Screener and Opioid Assessment for Patients with pain – Revised (SOAPP-R): Butler et al. Journal of Pain. 2008;9: Collateral information: family, friends, physicians, pharmacists CURES report

Opioid Risk Tools ORT: scores to place in low, mod, high risk – Family Hx of substance abuse – Personal Hx of Substance abuse – Hx of preadolescent sexual abuse – Psych disease (depression separate) – Age, Sex SOAPP-R: 24 ?’s self admin 1-4 scale totaled – e.g: “How often do you feel bored?” – “How often have you been sexually abused?” – “How often have you felt impatient with your doctors?”

Controlled Substance Utilization Review and Evaluation System – “CURES” Office of state Attorney General – Online “Prescription Drug Monitoring Program” generates “patient activity report” Initial register online at: http//ag.ca.gov/bne/cures.php Then must submit written application with notarized copies of DEA and medical licenses, govt. issued ID

Decision Phase – Goals and Conditions of Opioid Rx Goals – Analgesia – Improved function: physical, social, vocational and recreational – Ask question what can patient realistically hope to be able to do that they cannot do now? Important to realize that the evidence for opioid efficacy mostly comes from survey and uncontrolled case series, therefore each patient is his/her “n of 1” trial.

Decision Phase – Goals and Conditions of Rx (cont.) Conditions of Rx “universal precautions” – Treatment agreement - verbal or written? – Informed consent/education – One prescriber/one pharmacy – Visit frequency – No early refills – Pill counts? – Urine tox screens?

Urine Drug Tests - An Objective Tool Shows patient is taking what they are prescribed and not other substances Aberrant behavior present Aberrant behavior absent total POSITIVE urine 10 (8%)26 (21%) 36 (29%) NEGATIVE urine 17 (14%)69 (57%) 86 (71%) 27 (22%)95 (78%)122 Katz NO. et al. Clinical J of Pain. 2002

Decision Phase – Goals and Conditions for Rx Exit plan - mutually agreed upon criteria – Lack of adequate analgesia – Lack of adequate functional improvement – Persistent, intolerable side effects – Aberrant behaviors

Implementation Phase Dose initiation and titration – How long is long enough? [2 months] – How much is too much? [200mg daily oral morphine equiv dose] Higher doses – refer to specialty pain clinic Ballantyne, JC and Mao, JM. Opioid Therapy for Chronic Pain. NEJM.2003;349: Management of side effects

Outcomes Phase – When Goals are Met: Monthly med renewal visits – Document pain score and side effects – Treat side effects – Tox screen if indicated Comprehensive Reassessment visits Q 3-6 months The “4 A’s” – Analgesia? – Activity? – Acceptable SE profile? – Aberrant behaviors? “collateral” information remains important

Outcome Phase – The Dark Side of Opioids Goals not met Excessive side effects Ineffective analgesia - disease progression - tolerance - opioid resistant pain - opioid induced hyperalgesia - opioid induced toxicity Aberrant opioid-related behaviors - non-addiction - addiction

Opioid-induced Hyperalgesia vs. Opioid Toxicity Opioid-Induced Hyperalgesia – Anesthesia/pain literature – Setting of chronic, non-terminal pain syndromes – Continued poor pain control despite moderate opioid doses (>200mg/day) – Diffuse pain, out of previous distribution – Absence of neuroactivation – Absence of dehydration, renal failure – RX: dose reduction and opioid rotation (NMDA antagonists?) Opioid toxicity – Palliative Care/oncologic literature – Increase in pain despite rapid titration – Allodynia, hyperalgesia – Signs of neuroactivation: myoclonus, delirium – Dehydration, renal failure – RX: opioid rotation with marked reduction in dose, benzos, hydration? Lee, M et al. Pain Physician. 2011;14: Silverman, S. Pain Physician. 2009; 12:679-84

“Confusing Panopoly of Terms and Definitions” Addiction Habituation Dependence Substance abuse Substance dependence Substance misuse Physical dependence Psychological dependence

Evolution of Terminology Liaison Committee on Pain and Addiction (LCPA) – American Pain Society – American Academy of Pain Medicine – American Society of Addiction Medicine – created consensus definitions

LCPA Consensus Definitions “Addiction” favored over “dependence” Clear separation of concepts of physical dependence, tolerance, and addiction Addiction as a chronic disease Utility of distinguishing addiction from other forms of aberrant drug behavior

Tolerance “a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time”

Physical Dependence “a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid does reduction, decreasing blood level of the drug, and/or administration of an antagonist.”

Addiction “a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving”

Addiction

Addiction

Addiction

Addiction

Aberrant Opioid-Related Behaviors Examples of non-addiction aberrant behaviors: – Noncompliance – Diversion – Seeking euphoria – Medical “coping” – Pseudoaddiction

Chronic Pain Population on Opioids Aberrant Opioid-Related Behaviors Addiction

Behaviors LESS indicative of addiction Anxiety over symptoms Med hoarding Taking other’s meds Requesting a specific med Openly getting meds from other providers Complaints about needing higher dose Behaviors MORE indicative of addiction Buying street drugs Illegal activities Multiple lost or stolen meds Prescription forgery Injection or snorting meds Performed sex for drugs Resistance to med change despite SEs Passik SD, et. al. Clinical J Pain. 2006;22:

Aberrant Opioid-Related Behavior Survey Tools Addiction Behaviors Checklist Wu, et al. J. Pain Symp Manage. 2008;32(4): – Clinician considers presence of behaviors since last visit and within current visit – e.g. ran out of meds early? Reports worsening relationship with family? Current Opioid Misuse Measure Butler, et al. Pain. 2007;130: – 17 questions asked of patient with 0-4 response

Chronic Pain Population on Opioids Aberrant Opioid-Related Behaviors Addiction % 2-5%

Personal Observations from Dealing with Challenging Patients Assuming opioids = only way to Rx severe pain Multiple opioids of same type High doses without pain specialist input Continued dose escalation despite lack of significant improvement Absence of weighing benefit against risk Assuming aberrant behaviors = addiction

Having the Conversation Clearly lay out my concerns – – I first focus on lack of analgesia and side effect – Then discuss specific examples of aberrant opioid- related behaviors Present your assessment that risk of harm is greater than benefit – If I have relationship with patient, I focus on my wanting the best for them – If first visit, I focus on my ethical obligation to “do no harm” Refer back to opioid agreement if you have one

Having the Conversation (cont.) “It doesn’t make sense to keep doing something that is more likely to harm you than help you, does it?” I acknowledge that this is not an easy problem to deal with Don’t back them into a corner - I remind them; – My diagnosis could be wrong – I would not be offended if they transferred care to another physician – I will not abandon them.

Having the Conversation (cont.) I offer choice around how opioids are tapered, not if they will be tapered, with as much flexibility as is safe. Try to decide: tapering because of addiction or because of opioid side effects and/or failure? – Addiction should include in the care plan referral for recovery treatment – Addiction may require medication assisted treatment: methadone or buprenorphine

Insanity: doing the same thing over and over again and expecting different results - Albert Einstein

RECOVERY

janussc.org